Product Expansion Strong recent FDA-cleared launches including PsiF DNA System and PsiF DNA Sacroiliac Joint Stabilization System indicate ongoing product portfolio expansion. Potential sales opportunities lie in targeting spine, SI joint, and fusion market segments with bundled solutions and training for surgeons.

Strategic Partnerships Co development with SpineGuard and a US distribution partner shows openness to collaboration and external ecosystem leverage. Sales outreach should center on channel partnerships, co marketing initiatives, and joint field deployments to accelerate adoption.

Debt Milestones Milestones around debt settlement enabling the sale of the US subsidiary suggest transitional ownership dynamics and potential for accelerated market entry or restructured commercial arrangements. Explore opportunities tied to new ownership, distribution rights, and service scope expansions.

Market Footprint Active presence at industry events such as NANS and SA conferences signals visibility among neuromodulation and spine surgeons. Leverage event-based outreach, key opinion leader engagement, and trade show collaboration to generate high-intent leads.

Competitive Positioning Smaller high growth player with FDA cleared implants and focus on engineering driven patient care offers a niche for hospitals and clinics seeking innovative, cost efficient solutions. Target mid to large implant centers for pilot programs, training, and multi year supply contracts.